MEF2C and coronary artery disorder: This study demonstrated an elevated serum level of miR-499a-3p in CAD patients compared to healthy controls and confirmed that miR-499a-3p promotes proliferation and migration of endothelial cells and vascular smooth muscle cells via directly targeting myocyte enhancer factor 2C (MEF2C) at 3′-UTR [77].